Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first

Skip NavigationMarketsPre-MarketsU.S. MarketsEurope MarketsChina MarketsAsia MarketsWorld MarketsCurrenciesPrediction MarketsCryptocurrencyFutures & CommoditiesBondsFunds & ETFsBusinessEconomyFinanceHealth & ScienceMediaReal EstateEnergyClimateTransportationInvestigationsIndustrialsRetailWealthSportsLifeSmall BusinessInvestingPersonal FinanceFintechFinancial AdvisorsOptions ActionETF StreetBuffett ArchiveEarningsTrader TalkTechCybersecurityAIEnterpriseInternetMediaMobileSocial MediaCNBC Disruptor 50Tech GuidePoliticsWhite HousePolicyDefenseCongressExpanding OpportunityEurope PoliticsChina PoliticsAsia PoliticsWorld PoliticsVideoLatest VideoFull EpisodesLivestreamTop VideoLive AudioEurope TVAsia TVCNBC PodcastsCEO InterviewsDigital OriginalsWatchlistInvesting ClubTrust PortfolioAnalysisTrade AlertsMeeting VideosHomestretchJim's ColumnsEducationSubscribePROPro NewsJosh BrownMike SantoliCalls of the DayMy PortfolioLivestreamFull EpisodesStock ScreenerMarket ForecastOptions InvestingChart InvestingSubscribeLivestreamMenuMake ItselectUSAINTLLivestreamSearch quotes, news & videosLivestreamWatchlistSIGN INCreate free accountMarketsBusinessInvestingTechPoliticsVideoWatchlistInvesting ClubPROLivestreamMenu (function() { const userMembershipOnLastVisit = localStorage.getItem("cnbcMeta__cachedUserMembership"); if (!userMembershipOnLastVisit) { // If no user membership is stored, user is likely not logged in. // These users will typically see the banner. return; } const { isPro, isInvestingClubUser } = JSON.parse(userMembershipOnLastVisit); if (!(isPro || isInvestingClubUser)) { // We’re rendering the top banner for users who are not pro or investing club members. return; } // Hide the banner for pro and investing club users. const style = document.createElement("style"); style.id = "top-banner-placeholder-style"; style.innerHTML = "[data-top-banner-placeholder] { display: none; }"; document.head.appendChild(style); })() Business NewsWall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first Published Tue, Jul 21 20267:48 PM EDTUpdated An Hour AgoElaine Yu@yuenokAnniek Bao@in/anniek-bao-460a48107/@anniekbyxWATCH LIVEKey PointsSan Diego-based Axiom Biosciences plans to seek a primary listing in Hong Kong in 2027, followed by a secondary U.S. listing in 2029. Global biotech firms are increasingly eyeing Hong Kong for its growing investor base and its proximity to Chinese pharmaceutical partners, which could help speed up trials and lower costs.But local investors tend to favor companies with a clear China connection, according to life science-focused private equity firm Fontus Capital.In this article159892-CN9888-HKBIDUBABAFollow your favorite stocksCREATE FREE ACCOUNTHONG KONG, CHINA: Hong Kong has emerged as a major biotech fundraising hub, attracting dozens of Chinese biotech firms to list in the city.Cheng Xin | Getty Images News | Getty ImagesFor years, Chinese companies such as Alibaba and Baidu headed to the U.S. to list their shares, citing its deeper capital markets and higher valuations. Now, one American biotech firm is betting on doing the opposite.Axiom Biosciences, a San Diego-based developer of regenerative and genetic medicines, plans to go public in Hong Kong in 2027, followed by a secondary U.S. listing in 2029. The company says the "contrarian" move will open the door to sophisticated, biotech-focused investors while bringing it closer to clinical and commercial partners across Asia."Some of the most important science in the world is being built in the United States, but the way it gets funded hasn't kept pace," said Remo Moomiaie-Qajar, founder and CEO of Axiom. The Hong Kong exchange's stricter listing standards compared to the U.S. point to a mature biotech ecosystem, Moom